Drugs / NNC0363-0845
last change May 2022 re-read 2 minutes ago

NNC0363-0845

Developed for
type 1 diabetes mellitus
Investigated by
Novo Nordisk A/S

Trials 2 · a red edge is where a trial was stopped

202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05134987 Dec 2021 → May 2022 type 1 diabetes mellitus Novo Nordisk A/S Completed No outcome recorded
Phase 1 NCT04569994 Sep 2020 → Jun 2021 type 1 diabetes mellitus Novo Nordisk A/S Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as NNC0363-0845 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04569994
1

NCT05134987

Route Subcutaneous “A single dose administered s.c. (subcutaneously, under the skin)” NCT04569994